DNMT3A and acute myeloid leukemia: Several promising treatment strategies were recently reported, including the in vivo benefit of targeting aberrant epigenetics in MLL-PTD associated AML patients [28], the anti-leukemic activity of liposomal bortezomib delivered as a single agent in the MllPTD/wt:Flt3ITD/wt double knock-in mice through the pharmacologic increase in miR-29b [29], and dose intensification of anthracycline in induction therapy to improve the survival of AML patients with DNMT3A mutations and/or MLL-rearrangement [30].